XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.1
INVESTMENTS AND FAIR VALUE MEASUREMENTS
3 Months Ended
Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]  
INVESTMENTS AND FAIR VALUE MEASUREMENTS INVESTMENTS AND FAIR VALUE MEASUREMENTS
Marketable Securities
We invest surplus funds in excess of operational requirements in a diversified portfolio of marketable securities, with the objectives of delivering competitive returns, maintaining a high degree of liquidity, and seeking to avoid the permanent impairment of principal.
Our investments in marketable debt securities are classified and accounted for as available-for-sale. The marketable debt securities are classified either short-term or long-term based on each instrument’s underlying contractual maturity date. As of March 31, 2022 and December 31, 2021, we reported $11.2 million and $7.3 million of investments in debt securities as Marketable debt securities on our Condensed Consolidated Balance Sheets, respectively, as management intends to hold these investment for more than 12 months from the reporting date. We may sell certain marketable debt securities prior to their stated maturities for reasons including, but not limited to, managing liquidity, credit risk, duration and asset allocation.
Our investments in marketable equity securities are classified based on the nature of the securities and their availability for use in current operations. The marketable equity securities are measured at fair value with gains and losses recognized in Interest and other income (loss), net on our Condensed Consolidated Statements of Income and Comprehensive Income.
We regularly review our investment portfolio to identify and evaluate investments that have indicators of possible impairment. Investments are considered impaired when a decline in fair value is judged to be other-than-temporary. If the cost of an individual investment exceeds its fair value, we evaluate, among other factors, general market conditions, the duration and extent to which the fair value is less than cost, and our intent and ability to hold the investment. Once a decline in fair value is determined to be other-than-temporary, we will record an impairment charge and establish a new cost basis in the investment.
Marketable securities as of March 31, 2022 and December 31, 2021 consisted of following (in thousands):
March 31, 2022

Cost or Amortized Cost
Unrealized GainsUnrealized LossesFair Value
Mutual funds$40,023 $— $(1,601)$38,422 
Corporate bonds10,651 530 — 11,181 
Equity securities43,039 3,038 (967)45,110 
$93,713 $3,568 $(2,568)$94,713 
December 31, 2021
Cost or Amortized CostUnrealized GainsUnrealized LossesFair Value
Mutual funds$50,000 $— $(338)$49,662 
Corporate bonds6,996 290 — 7,286 
Equity securities38,100 — (1,331)36,769 
$95,096 $290 $(1,669)$93,717 

As of March 31, 2022 and December 31, 2021, marketable securities are classified and reported on our Condensed Consolidated Balance Sheets as follows:

March 31, 2022
Marketable Equity Securities Marketable Debt SecuritiesTotal
Mutual funds$38,422 $— $38,422 
Equity securities45,110 — 45,110 
Corporate bonds— 11,181 11,181 
$83,532 $11,181 $94,713 
December 31, 2021
Marketable Equity SecuritiesMarketable Debt SecuritiesTotal
Mutual funds$49,662 $— $49,662 
Equity securities36,769 — 36,769 
Corporate bonds— 7,286 7,286 
$86,431 $7,286 $93,717 
The amortized costs and fair value of our marketable debt securities, by contractual maturity, as of March 31, 2022 (in thousands) are as follows:
March 31, 2022
Amortized
Cost
Fair
Value
Less than 1 year$— $— 
1 to 5 years10,651 11,181 
Total$10,651 $11,181 
Derivative Financial Instruments
We invest in derivatives that are not designated as hedging instruments and which consist of call and put options. When we sell call and put options, the premium received is reported as Other current liabilities on our Condensed Consolidated Balance Sheets. When we purchase put or call options, the premium paid is reported as Marketable securities on our Condensed Consolidated Balance Sheets. The carrying value of these options are adjusted to the fair value at the end of each reporting period until the options expire. Gains and losses recognized from the periodic adjustments to fair value are recognized as Interest and other income, on our Condensed Consolidated Statements of Income and Comprehensive Income.
Our derivative instruments which consisted of call and put options sold at their fair value as of the balance sheet date. These derivative instruments are reported as Other current liabilities on our Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 (in thousands).
March 31, 2022
CostUnrealized LossesFair Value
Derivative instruments$8,392 $2,558 $10,950 
$8,392 $2,558 $10,950 
December 31, 2021
CostUnrealized GainsFair Value
Derivative instruments$6,370 $(103)$6,267 
$6,370 $(103)$6,267 

A summary of realized and unrealized gains and losses from our equity securities and derivative instruments are as follows (in thousands):
Three Months Ended
March 31,
20222021
Net unrealized gains recognized on marketable equity securities $2,140 $— 
Net realized gains recognized on marketable equity securities1,026 — 
Net unrealized losses recognized on derivative instruments(2,661)— 
Net realized loss recognized on derivative instruments(134)— 
Net realized gains recognized on marketable debt securities368 — 
Total net gains recognized in interest and other income (loss), net$739 $— 
Fair Value Measurements
Our financial instruments measured at fair value on a recurring basis consisted of money-market funds, mutual funds, equity securities, corporate debt securities and derivatives. Equity securities are classified within Level 1 of the fair value hierarchy as they are valued based on quoted market price in an active market. Corporate debt securities and derivative instruments are valued based on quoted prices in markets that are less active, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency are generally classified within Level 2 of the fair value hierarchy.
Financial instruments valued based on unobservable inputs which reflect the reporting entity’s own assumptions or data that market participants would use in valuing an instrument are generally classified within Level 3 of the fair value hierarchy. We did not hold Level 3 financial instruments as of March 31, 2022 and December 31, 2021.
Financial instruments measured at fair value on a recurring basis as of March 31, 2022 and December 2021 are classified based on the valuation technique in the table below (in thousands):
March 31, 2022
Fair Value Measurements Using
Quoted Prices
 in Active
Markets for
Identical Assets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Total
Assets:
Mutual funds$38,422 $— $— $38,422 
Equity securities45,110 — — 45,110 
Corporate bonds— 11,181 — 11,181 
Total assets at fair value$83,532 $11,181 $— $94,713 
Liabilities
Derivative instruments$— $10,950 $— $10,950 
Total liabilities at fair value$— $10,950 $— $10,950 

December 31, 2021
Fair Value Measurements Using
Quoted Prices
 in Active
Markets for
Identical Assets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Total
Assets:
Mutual funds$49,662 $— $— 49,662 
Equity securities36,769 — — 36,769 
Corporate bonds— 7,286 — 7,286 
Total assets at fair value$86,431 $7,286 $— $93,717 
Liabilities
Derivative instruments$— $6,267 $— $6,267 
Total liabilities at fair value$— $6,267 $— $6,267